HALOZYME THERAPEUTICS, INC. Cash and Cash Equivalents
HALOZYME THERAPEUTICS, INC. (HALO) had Cash and Cash Equivalents of $163.14 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-06
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $163.14M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $309.75M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $133.82M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $419.67M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $163.14M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $309.75M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $133.82M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $419.67M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $61.86M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $176.33M 10-Q · filed 2026-05-11 | |
| 2024-12-31 | $115.85M 10-K · filed 2026-02-17 | |
| 2024-09-30 | $154.32M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $187.86M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $164.63M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $118.37M 10-K · filed 2026-02-17 | |
| 2023-09-30 | $274.23M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $221.16M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $96.38M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $234.19M 10-K · filed 2024-02-20 | |
| 2022-09-30 | $147.16M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $90.93M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $117.83M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $118.72M 10-K · filed 2023-02-21 | |
| 2021-09-30 | $491.68M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $446.97M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $499.45M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $147.70M 10-K · filed 2022-02-22 | |
| 2020-09-30 | $65.74M 10-Q · filed 2020-11-02 | |
| 2020-06-30 | $133.61M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $104.82M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $120.18M 10-K · filed 2021-02-23 | |
| 2019-09-30 | $59.20M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $67.04M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $60.59M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $57.94M 10-K · filed 2020-02-24 | |
| 2018-09-30 | $55.02M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $55.17M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $98.01M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $168.74M 10-K · filed 2019-02-21 | |
| 2017-09-30 | $164.40M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $114.75M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $45.19M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $66.76M 10-K · filed 2018-02-20 | |
| 2016-09-30 | $61.21M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $61.23M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $69.09M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $43.29M 10-K · filed 2017-02-28 | |
| 2015-09-30 | $71.51M 10-Q · filed 2016-11-07 | |
| 2015-06-30 | $67.77M 10-Q · filed 2016-08-09 | |
| 2015-03-31 | $44.29M 10-Q · filed 2016-05-09 | |
| 2014-12-31 | $61.39M 10-K · filed 2017-02-28 | |
| 2014-09-30 | $46.38M 10-Q · filed 2015-11-09 | |
| 2014-06-30 | $56.13M 10-Q · filed 2015-08-10 | |
| 2014-03-31 | $76.57M 10-Q · filed 2015-05-11 | |
| 2013-12-31 | $27.36M 10-K · filed 2017-02-28 | $27.36M 10-K · filed 2014-02-28 |
| 2013-09-30 | $17.49M 10-Q · filed 2014-11-10 | $17.49M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $27.93M 10-Q · filed 2014-08-11 | $27.93M 10-Q · filed 2013-08-07 |
| 2013-03-31 | $39.02M 10-Q · filed 2014-05-12 | $39.02M 10-Q · filed 2013-05-08 |
| 2012-12-31 | $99.50M 10-K · filed 2016-02-29 | $99.90M 10-K · filed 2013-03-01 |
| 2012-09-30 | $87.61M 10-Q · filed 2013-11-08 | |
| 2012-06-30 | $102.04M 10-Q · filed 2013-08-07 | |
| 2012-03-31 | $116.61M 10-Q · filed 2013-05-08 | |
| 2011-12-31 | $52.38M 10-K · filed 2015-03-02 | $52.83M 10-K · filed 2012-03-12 |
| 2011-09-30 | $66.33M 10-Q · filed 2012-11-08 | |
| 2011-06-30 | $79.12M 10-Q · filed 2012-08-09 | |
| 2011-03-31 | $73.83M 10-Q · filed 2012-05-07 | |
| 2010-12-31 | $82.76M 10-K · filed 2014-02-28 | $83.26M 10-Q · filed 2011-08-05 |
| 2010-09-30 | $89.84M 10-Q · filed 2011-11-08 | |
| 2010-06-30 | $41.31M 10-Q · filed 2011-08-05 | |
| 2009-12-31 | $67.46M 10-K · filed 2013-03-01 | |
| 2008-12-31 | $63.72M 10-K · filed 2012-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |